Ozge Aybi

Ozge Aybi

Auto-generated profile, based on publicly available information

Ozge Aybi

Division of Rheumatology, Department of Internal Medicine, Hacettepe University Faculty of Medicine, Ankara, Turkey

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2020 in Annals of the Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
OGOnay Gercik
Onay Gercik
EBEmre Bilgin
Emre Bilgin
DSDilek Solmaz
Dilek Solmaz
FCFulya Cakalagaoglu
Fulya Cakalagaoglu
ASArzu Saglam
Arzu Saglam
SAServet Akar
Servet Akar

25 April 2019 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
EBEmre Bilgin
Emre Bilgin
ÖDÖmer Dizdar
Ömer Dizdar
DGDeniz Can Guven
Deniz Can Guven
SCSerdar Ceylan
Serdar Ceylan
ÖAÖzge Aybi
Özge Aybi
SOSeza Ozen
Seza Ozen

12 October 2026 in Clinical and Experimental Medicine
Verified
Journal Article
Open access
PDF file
OGOnay Gercik
Onay Gercik
EDElif Durak-Ediboğlu
Elif Durak-Ediboğlu
EBEmre Bilgin
Emre Bilgin
DSDilek Solmaz
Dilek Solmaz
ASArzu Saglam
Arzu Saglam
SAServet Akar
Servet Akar
Introduction: ANCA-associated vasculitis (AAV) is a heterogeneous disease associated with substantial morbidity and mortality; however, data integrating both mortality and kidney outcomes within real-world cohorts remain limited. Objective: To evaluate mortality and kidney outcomes in AAV and to identify clinical determinants of first-year and overall mortality as well as progression to end-stage kidney disease (ESKD). Methods: Medical records of patients with AAV from two tertiary referral centers were retrospectively reviewed. Kidney survival and mortality were analyzed using Kaplan–Meier and Cox proportional hazards models. Results: A total of 248 patients (54% male; mean age 51.6 ± 15.6 years) were included. Kidney involvement was present in 73% of patients, and 33% of patients with kidney involvement progressed to ESKD. MPO-ANCA–positive patients had shorter kidney survival ( p = 0.037). The 1- and 5-year overall survival rates were 90.2% and 81.9%, respectively. In multivariable analyses, older age at diagnosis and lower baseline eGFR were consistently associated with higher mortality. Higher serum creatinine was independently associated with ESKD, while hemodialysis requirement at diagnosis was independently associated with ESKD in an alternative model. For first-year mortality, pulmonary and cardiac involvement were also independently associated with mortality, whereas baseline BVAS was independently associated with overall mortality in an alternative model. Conclusion: In this real-world cohort, mortality and kidney outcomes in AAV were primarily associated with baseline kidney function and age. These findings highlight the importance of baseline clinical and renal assessment for mortality and kidney outcome stratification in AAV.